PRONECOVID19: Prone Positioning Short-term Effects on Tissue Oxygen Saturation in Critical COVID-19 Patients

Sponsor
Corporacion Parc Tauli (Other)
Overall Status
Recruiting
CT.gov ID
NCT04692129
Collaborator
Institut de Ciències Fotòniques (ICFO) (Other), Centre de Recerca Matemàtica (Other), Institute of Physics University of Campinas (Other)
100
6
29.1
16.7
0.6

Study Details

Study Description

Brief Summary

The purpose of this study is to monitor short-term changes in tissue oxygen saturation and local blood flow as results of changing from supine to prone position in ARDS COVID-19 patients

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    After obtaining consent to participate in the study, the subjects included in the study will undergo a baseline 15-minute measurement of tissue oxygen saturation (StO2) measured non-invasively on the forearm by means of near-infrared spectroscopy (NIRS). Once a baseline stable StO2 value is obtained, a provocative test, consisting of a transient vascular occlusion, will be performed. The test will allow the obtention of a local metabolic rate, and a StO2 recovery rate after the ischemic stimulus.

    Tissue oxygenation measurements will be performed in supine position, immediately before changing to prone positioning, and repeated after 20 minutes of stabilization, once in prone position.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    100 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Short-term Effects of Prone Positioning on Tissue Oxygen Saturation, Measured by Near-infrared Spectroscopy, in COVID-19 Patients With Acute Respiratory Distress Syndrome
    Actual Study Start Date :
    May 29, 2020
    Anticipated Primary Completion Date :
    Oct 31, 2022
    Anticipated Study Completion Date :
    Oct 31, 2022

    Outcome Measures

    Primary Outcome Measures

    1. Change in tissue oxygenation (StO2) [20 minutes]

      Tissue oxygenation is measured as percent of oxyhemoglobin over total hemoglobin content in the sensed area (skeletal muscle)

    2. Change in local hemoglobin content (THC) [20 minutes]

      THC is measured as microMols

    Secondary Outcome Measures

    1. Compare changes in tissue oxygenation (StO2) and arterial oxygenation (SaO2) [20 minutes]

      Arterial oxygenation (SaO2) is obtained from blood gas analysis, from an arterial blood sample, while StO2 is derived from the sensed tissue, by means of NIRS/DCS technology

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • COVID-19 patients admitted in the ICU receiving invasive mechanical ventilation and requiring prone positioning for severe hypoxemia management, as decided by the medical team
    Exclusion Criteria:
    • Severe peripheral vasculopathy

    • Raynaud's syndrome

    • Skin lesions/trauma in upper limbs interfering the placement of the NIRS probe and/or the occlusion tourniquet

    • Deep venous thrombosis in the upper limbs

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Hospital de Clñinicas da UNICAMP Campinas Sao Paulo Brazil
    2 Hospital General de México México Mexico
    3 Parc Taulí Hospital Universitari Sabadell Barcelona Spain 08208
    4 Hospital Clínic i Provincial de Barcelona Barcelona Spain
    5 Hospital Parc Salut Mar Barcelona Spain
    6 Hospital Vall d'Hebron Barcelona Spain

    Sponsors and Collaborators

    • Corporacion Parc Tauli
    • Institut de Ciències Fotòniques (ICFO)
    • Centre de Recerca Matemàtica
    • Institute of Physics University of Campinas

    Investigators

    • Principal Investigator: Jaume Mesquida, Parc Taulí Hospital Universitari

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Jaume Mesquida, Principal Investigator, Corporacion Parc Tauli
    ClinicalTrials.gov Identifier:
    NCT04692129
    Other Study ID Numbers:
    • 2020/591
    First Posted:
    Dec 31, 2020
    Last Update Posted:
    Jul 28, 2022
    Last Verified:
    Jul 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Jaume Mesquida, Principal Investigator, Corporacion Parc Tauli
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 28, 2022